Kornimate/medical-research-clean huggingface dataset:
the effects of autologous slet

Conditions: Limbal Stem-cell Deficiency

Summary: this study aims to prospectively evaluate the therapeutic effects of autologous simple limbal epithelial transplantation for patients with limbal stem cell deficiency. the change of visual acuity, quality of life and so on will be monitored before and after surgery.

human corneal epithelial cells are stratified squamous cells that cover the corneal surface. these cells are regenerated from cells known as limbal stem cells (lscs) that grow continuously and proliferate from the limbus. failure or damage at the limbal zone can occur from hereditary or acquired causes such as ocular burns, trauma, or diseases such as stevens- johnson syndrome, leading to limbal stem cell deficiency (lscd). the treatment of lscd includes transplantation of healthy limbal tissue or cultured limbal epithelial cells. in the last two decades, cultivated limbal epithelial transplantation (clet) has been a widely used technique. in 2012, sangwan and coworkers proposed a novel technique that they named simple limbal epithelial transplantation (slet) for the treatment of unilateral lscd1. slet could have benefits for those centers that do not have the ability to perform cultivated limbal epithelial transplantation (clet) preparation and could be especially useful for those countries that cannot afford a gmp center. therefore, slet is quickly gaining popularity in countries like india. as it is a relatively new technique, its long-term clinical effectiveness (similar to what is observed in clet) must be noted before determining its actual benefits.our study aims to prospectively evaluate the therapeutic effects of autologous simple limbal epithelial transplantation for patients with limbal stem cell deficiency. the change of visual acuity, quality of life and so on will be monitored before and after surgery. in this study, the effects of autologous simple limbal epithelial transplantation will be investigated.

Eligibility criteria:
inclusion criteria: 1. age 10-90 years old 2. the lesion eye has at least grade 2 limbal stem cell deficiency 3. the lesion eye has limbal stem cell deficiency causing recurrent corneal erosion and neovascularization ingrowth 4. the symptoms last for at least 6 months and do not improve with medication exclusion criteria: 1. symptoms improve spontaneously or under medication 2. someone who can not be examined regularly after the operation 3. someone with poor prognosis 4. severe lagophthalmos or trichiasis that has not been corrected 5. ocular infection
uniform fdg-pet guided gradient dose prescription to reduce late radiation toxicity

Conditions: Head and Neck Neoplasms; Carcinoma, Squamous Cell

Summary: the objective of the upgrade-rt trial is to investigate whether de-escalation of elective radiation dose and introduction of an intermediate dose-level in the treatment of head and neck cancer will results in less radiation sequelae and improved quality of life after treatment whilst the recurrence rate in electively irradiated lymph nodes should not be compromised. a summary of the study protocol can be found here: http://rdcu.be/qgmv


Eligibility criteria:
inclusion criteria: 1. newly diagnosed tumours classified as stage t2-4 n0-2 (tnm 7th edition 2009) located in the larynx, oropharynx or hypopharynx (unknown primary and oral cavity are not eligible) 2. histopathological diagnosis of invasive squamous cell carcinoma in the primary tumour 3. decision for curative intent external beam radiotherapy with elective treatment of the neck made by a multidisciplinary head-and-neck oncology team. the patient must be expected to complete the treatment. 4. radiotherapy planned to start within 6 weeks from baseline imaging of tumour assessment 5. no distant metastasis (m0) (tnm 7th edition 2009) 6. who performance status 0-2 7. ≥ 18 years of age 8. written informed consent exclusion criteria: 1. concomitant chemotherapy or egfr inhibitors for this tumour. 2. primary tumour of the oral cavity or unknown primary tumour 3. prior or current anticancer treatment to the head and neck area (e.g. radical attempted or tumour reductive surgery, neo-adjuvant or concomitant chemotherapy, egfr inhibitors or radiotherapy), except for endoscopic glottic laser micro surgery. 4. current participation in any other oncologic interventional clinical study for this tumor. 5. uncontrolled diabetes mellitus. 6. known or suspected hiv infection. 7. history of previous malignancy within the last 3 years, with the exception of surgically cured carcinoma in situ of the cervix, in situ breast cancer, incidental finding of stage t1a or t1b prostate cancer, basal/squamous cell carcinoma of the skin, and other non-invasive malignancies (e.g. in situ carcinomas).. 8. any condition (somatic, psychological, familial, sociological or geographical) rendering the patient unable to understand or complete questionnaires.

Keywords: head and neck cancer accelerated radiotherapy dose reduction dose de-escalation elective lymph nodes fdg-pet
studying biomarker expression in samples from patients with down syndrome and acute myeloid leukemia or other transient myeloproliferative disorder

Conditions: Leukemia

Summary: rationale: studying samples of blood, tissue, and bone marrow from patients with cancer in the laboratory may help doctors learn about changes that occur in rna and identify biomarkers related to cancer. purpose: this research trial studies rna samples from patients with down syndrome and acute myeloid leukemia or other transient myeloproliferative disorder.

objectives: * to compare mirna expression in distinctive diagnostic groups: transient myeloproliferative disorder (tmd), down syndrome (ds) acute megakaryocytic leukemia (amkl), non-ds amkl, and in remission ds samples (representing germline, non-malignant samples). outline: archived rna samples are analyzed for mature micro (mi)rna expression by real-time rt-pcr. results are then compared with mirna expression of non-down syndrome patients with acute megakaryocytic leukemia.

Eligibility criteria:
disease characteristics: * patients with down syndrome (ds) diagnosed with acute myeloid leukemia or transient myeloproliferative disorder * clinical samples obtained from patients enrolled on the cog aaml0431 and cog aaml08b1 patient characteristics: * previously consented to biologic studies prior concurrent therapy: * see disease characteristics

Keywords: childhood acute myeloid leukemia in remission childhood acute myeloid leukemia/other myeloid malignancies childhood acute megakaryocytic leukemia (m7)
the effects of sex hormones on cognition and mood in older adults

Conditions: Cognition Disorders; Mood Disorders

Summary: this study is investigating the effects of hormone replacement therapy on memory, mental abilities and mood in older adults aged 65-90. during the nine month long study, men will take testosterone for three months and women will take estrogen for three months. at four points during the study (once every three months), participants will complete a test battery and have blood drawn.

double-blind, placebo-controlled, crossover study investigating the effects of estrogen replacement and testosterone replacement on cognition and mood in older adults. women who have not had a hysterectomy will be given prempro (estrogen with progesterone to protect the uterine lining), and hysterectomized women will be given premarin (estrogen only).

Eligibility criteria:
inclusion criteria: * women and men aged 65-90 who have not received hormone replacement for the last three months. exclusion criteria: * previous head injury with loss of consciousness for more than one hour. * men with a history of prostate cancer. * men on testosterone replacement within the past three months. * women with a history of breast or uterine cancer. * women on estrogen replacement within the past three months.

Keywords: emotions cognition aging memory
the clinical feasibilityof a multi-modal photoacoustic/ultrasonic imaging system in rheumatoid arthritis

Conditions: Rheumatoid Arthritis; Ultrasonography

Summary: new type of imaging method is in demand clinically for early detection and treatment guiding of ra. photoacoustic imaging (pai), a hot spot in medical imaging society, which combines the merits of optical imaging and us and has a capacity in morphological, functional and molecular imaging, has shown potential in visualizing superficial organs, including small joints. the investigators developed a multi-modal photoacoustic/ultrasound (pa/us) imaging system, equipped with a handheld 3d pa/us probe, which wass able to provide 3d volume data of dual-wavelength pa imaging of small joints, in addition to real-time 2d pa/us imaging. the investigators plan to recruit ra patients in different disease conditions and healthy volunteers to receive the 2d and 3d pa/us examination on the 2nd and 3rd mcp, pip joints and wrist joints using this imaging system, and to evaluate the potential clinical role of the imaging system in ra, and its added value to current imaging methods.

the multi-modal pa/us imaging system was built on a high-end commercial us platform, and allowed real-time imaging of grey-scale us imaging, color-doppler us (cdus) imaging and dual-wavelength pa imaging. the pa/us images were acquired using a hand-held probe integrated optical devices and us transducers. 3d volume data of the selected joint of each participant was collected using an automatic scanning device after the dual-modal imaging. the investigators plan to recruit ra patients from the outpatient department of rheumatology of our hospital, who have been diagnosed as ra by experienced rheumatologists. the patients and healthy volunteers will receive multi-modal imaging examinations using the novel imaging system. the mcp 2 and 3, pip 2 and 3, and wrist of bilateral hand were chosen for the multi-modal imaging. conventional us scanning of the joints, including grey-scale us, cdus, and pdus, will be carried out by an experienced us operator. afterwards, 2d and 3d pa/us imaging will be implemented for each joint by the same operator. all of the imaging data will be analysed by the matlab software.

Eligibility criteria:
the inclusion criteria 1. the patients were above 18 years-old; 2. the patients were diagnosed with ra according to the american college of rheumatology (acr) criteria, and the current clinical state was in-active or relapse; 3. the patients were consent to receive examinations of photoacoustic imaging. the exclusion criteria 1. the patients had mental disease or other severe diseases, and were not capable of receiving imaging examinations; 2. the patients had strong reaction to laser light.

Keywords: rheumatoid arthritis ultrasonography multi-modal imaging photoacoustic imaging
multiple sclerosis: chi3l1 and treatment efficacy

Conditions: Multiple Sclerosis

Summary: chitinase 3-like 1 (chi3l1) is a human protein synthetized by inflammatory cells. its serum level increases in case of autoimmune diseases, and especially during multiple sclerosis (ms). there is a need for biological markers predictive of treatment efficacy. ms outcomes one year from treatment initiation are predictive of long-term treatment efficacy. the hypothesis is that serum chi3l1 level before treatment initiation could predict one year ms outcomes. primary objective: to show an association between the serum chi3l1 level at diagnostic assessment and the clinical and radiological efficacy one year from initiation of the first disease modifying treatment (interferon beta, dimethyl fumarate or teriflunomide) in relapsing-onset multiple sclerosis (ms). secondary objectives: to determine the threshold value of the serum chi3l1 level predicting the efficacy of treatment, and the added value of other potential biomarkers in cerebrospinal fluid collected at diagnostic assessment: chi3l1, light chains of neurofilaments and interleukin 6.


Eligibility criteria:
inclusion criteria: * relapsing-onset multiple sclerosis according to the 2017 mcdonald criteria * blood and cerebrospinal fluid samples collected at diagnostic assessment from 2012 january 1st and kept in the centre de ressources biologiques lorrain * first platform disease modifying drugs : interferon-beta, dimethyl fumarate or teriflunomide, introduced during the first 3 months after the diagnostic assessment * disease modifying drugs maintained at least 3 months * follow-up during at least 15 months after the first disease modifying drug initiation * at least one brain magnetic resonance imaging with gadolinium injection between months 3 and 15 after disease modifying drug initiation exclusion criteria: * objection to the use of personal data for research purpose
comparison of face to face lecture, interactive internet based and computer based teaching

Conditions: 3rd Year Medical School's Students

Summary: the investigators carried out a randomized controlled trial comparing three methods of teaching. these three instructional methods consist of face to face lecture, interactive internet based teaching and computer based teaching (lecture synchronized with presentation). the hypotheses tested were: a) whether there is a difference between these three methods in knowledge achievement and b) whether there is a difference between students satisfaction in three groups.


Eligibility criteria:
inclusion criteria: * 3rd year medical school's students exclusion criteria: * it must be their first experience of the course and they must have no previous elective or obligatory study about teaching topic (multiple myeloma).
semi-automated segmentation methods of sstr pet for dosimetry prediction

Conditions: Refractory Meningioma

Summary: tumor dosimetry with somatostatin receptor-targeted peptide receptor radionuclide therapy (sstr-targeted prrt) by 177lutetium-dotatate might contribute to improve follow-up and treatment response of refractory meningiomas. this study aims to evaluate standard uptake value mean (suvmean) as a tumoral absorbed dose predictive predictive factor and propose semi-automated segmentation method to determine metabolic tumor volume with pretherapeutic 68-gallium-dotatoc pet.


Eligibility criteria:
inclusion criteria: * patients with meningioma exclusion criteria: - pet scan not available
evaluation of subcutaneous immunotherapy towards pollen in children

Conditions: Rhinitis, Allergic; Conjunctivitis, Allergic; Asthma

Summary: the objective is to prospectively explore associations between immunological parameters in blood and clinical effect of subcutaneous immunotherapy (scit) in children with severe allergy towards pollen. half of the children will receive scit while the other half will start scit after the study is finished. clinical evaluations of symptoms and an immunological survey will be performed before start of scit and after one year of treatment. some of the immunological parameters will also be checked after 6 months of treatment

before start of scit, with alutard pollenextract/s from " allergologisk laboratorium köbenhavn" (alk), and after one year of treatment, immunoglobulin e (ige)-antibody levels towards the crude allergen and important allergen components in birch and grasspollen (timothy) will be measured in blood. while ige- antibodies are considered to be an indicator of allergy igg- and igg4-antibodies are considered to be "blocking" antibodies in ige-mediated allergy. therefore the investigators will measure the igg- and igg4-antibody levels to crude allergens and applicable allergen components before start, when maintenance dose is reached (after 6 months) and after one year of treatment. in order to evaluate quality of life, a validated form (disabkids) will be used. symptom score will be rated by a validated form (lila). the need for medication to treat allergic rhinitis and asthma will be assessed using questionnaires. a conjunctival provocation with the applicable allergen(s) will be performed before start of scit and after one year of treatment.

Eligibility criteria:
inclusion criteria: * seasonal rhinoconjunctivitis caused by grass and/or birch pollen allergy * insufficient clinical effect of symptomatic treatment (antihistamine, nasal corticosteroids) * ige antibodies to grass and/or birch pollen antigens exclusion criteria: * severe comorbidity, severe asthma, pregnancy
efficacy of a telmisartan/s-amlodipine on 24-hour bp control in hypertensive patients inadequately controlled

Conditions: Hypertension

Summary: to evaluate the efficacy of the timing of the administration of a telmisartan/s-amlodipine (telminuvo®tab. 40/2.5mg) on 24-hour bp control in hypertensive patients inadequately controlled by telmisartan monotherapy

a multicenter, prospective, randomized, open-label, phase 4 trial designed to evaluate the efficacy of the timing of the administration of a telmisartan/s-amlodipine(telminuvo®tab. 40/2.5mg) on 24-hour bp control in hypertensive patients inadequately controlled by telmisartan monotherapy

Eligibility criteria:
inclusion criteria: 1. more than 20 years in hypertension patient 2. hypertension is satisfied with the clinic blood pressure that was measured at the time of screening * treatment-naive: clinic mean sitting diastolic blood pressure ≥ 100mmhg. * treatment-experienced: clinic mean sitting diastolic blood pressure ≥ 90mmhg. 3. hypertension is satisfied with the clinic blood pressure that was measured at the time of randomization * clinic mean sitting diastolic blood pressure ≥ 90mmhg 4. patient who decided to participate and signed on an informed consent form willingly exclusion criteria: 1. clinic mean sitting systolic blood pressure ≥ 180mmhg or clinic mean sitting diastolic blood pressure ≥ 115mmhg at the time of screening and randomization 2. as night workers who sleep during the day and whose working hours including 00:00 to 04:00 3. secondary hypertension 4. severe heart disease(heart failure; new york heart association(nyha) class 3, 4) and recent unstable angina or myocardial infarction or valvular heart disease or arrhythmia requiring treatment within the past 3 months 5. severe cerebrovascular disorders such as cerebral infarction, cerebral hemorrhage within 6 months 6. type 1 diabetes mellitus or uncontrolled type 2 diabetes mellitus(hba1c \> 8.0%) 7. severe or malignant retinopathy 8. abnormal laboratory test results * aspartate aminotransferase/alanine aminotransferase \> upper normal limit x 2 * serum creatinine \> upper normal limit x 2 9. acute of chronic inflammatory status requiring treatment 10. need for other antihypertensive drugs during the trial 11. need for prohibited medication specified in the protocol 12. a history of angioedema with ace inhibitors or angiotensin-ⅱ receptor blockers 13. severe hypersensitivity to amlodipine or telmisartan 14. history of drug or alcohol abuse within 6 months 15. surgical or medical conditions * history of major gastrointestinal surgery * history of active inflammatory bowel syndrome within 12 months * abnormal pancreatic functions * gastrointestinal/rectal bleeding * urinary tract obstruction 16. administration of other investigational product within 30 days 17. pregnant, breast-feeding and childbearing age who don't use adequate contraception 18. history of malignant tumor within 5 years (including leukemia and lymphoma) 19. another clinical condition in investigator's judgement

Keywords: hypertension, telmisartan/s-amlodipine
venous thrombectomy/thrombolysis outcome registry

Conditions: Deep Venous Thrombosis; Post Thrombotic Syndrome

Summary: deep venous thrombosis affects more than 350,000 individuals each year in the u.s.the registry will track patient outcome and quality of life over 60 months for treatment with anticoagulation and elastic compression stockings and catheter-directed thrombolysis (cdt) in accordance with current treatment guidelines .


Eligibility criteria:
inclusion criteria: •data obtained in line with good clinical practice, applicable laws and regulation exclusion criteria: -

Keywords: cdt pcdt dvt pts quality of life
symbicort turbuhaler 30/60 special clinical experience investigation for long-term use for chronic obstructive pulmonary disease (copd) patients

Conditions: Chronic Obstructive Pulmonary Disease

Summary: the purpose of the investigation is to confirm the safety and efficacy in long-term use of symbicort turbuhaler in patients with chronic obstructive pulmonary disease (copd) under the post-marketing actual use.

symbicort turbuhaler 30/60 special clinical experience investigation for long-term use for copd patients

Eligibility criteria:
inclusion criteria: * among patients treated with symbicort turbuhaler due to chronic obstructive pulmonary disease(copd), those who received the drug for the first time.

Keywords: chronic obstructive pulmonary disease symbicort long-term use
chemotherapy in treating patients with retinoblastoma

Conditions: Retinoblastoma

Summary: rationale: drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. combining more than one drug may kill more tumor cells. purpose: phase ii trial to study the effectiveness of combination chemotherapy in treating patients with retinoblastoma.

objectives: i. estimate the response rate to adjuvant carboplatin (cbdca) alone in children with intraocular retinoblastoma. ii. assess the overall survival, disease-free survival, and time to treatment failure in these patients. iii. attempt to maintain a 90% disease-free survival rate with this treatment. iv. estimate the percentage of disease-free survivors who do not require the use of radiotherapy after adjuvant cbdca. v. assess the toxicity of this treatment. vi. estimate the percentage of functional eyes salvaged using this radiation-sparing protocol and compare these results, in a nonrandomized manner, with historical treatment results in this population. outline: patients are stratified according to vitreous disease (yes vs no). patients receive carboplatin iv over 1 hour on day 0. treatment repeats every 2-3 weeks for 2 courses. patients achieving complete response (cr) proceed to local control measures consisting of cryotherapy, laser photocoagulation, etc. (except brachytherapy). patients not achieving cr continue with carboplatin until local control measures feasible. patients with vitreous disease achieving cr receive 2 additional courses and then receive local control measures. patients with vitreous disease not achieving cr receive intensive chemotherapy. patients receive intensive chemotherapy consisting of vincristine iv on days 0, 7, and 14, cisplatin iv over 6 hours on day 0, etoposide iv on days 1 and 2, followed by cyclophosphamide iv over 60 minutes on days 1 and 2. patients receive filgrastim (g-csf) subcutaneously beginning on day 3 and until blood counts recover. treatment repeats every 2-4 weeks for 2 courses beyond cr. patients are followed for 3 years. projected accrual: a total of 50 patients will be accrued for this study over 5-6 years.

Eligibility criteria:
disease characteristics: intraocular retinoblastoma ophthalmologic exam under anesthesia within 3 weeks prior to registration no pathologic confirmation required no evidence of extraocular disease, i.e.: negative head mri or ct (contrast not required) negative csf cytology negative bone marrow aspiration and biopsy patient characteristics: age: under 18 performance status: not specified hematopoietic: not specified hepatic: bilirubin less than 2.0 mg/dl sgot or sgpt less than 5 times upper limit of normal renal: creatinine normal for age or creatinine clearance greater than 50 ml/min prior concurrent therapy: no prior chemotherapy or radiotherapy

Keywords: intraocular retinoblastoma